NOVATO, Calif., May 3, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an overview of the Company at two investor conferences in May.
The conference presentation schedule is as follows:
| Deutsche Bank 37th Annual Healthcare Conference |
| May 8, 2012 at 1:30pm ET |
| InterContinental, Boston, MA |
| Bank of America Merrill Lynch 2012 Healthcare Conference |
| May 16, 2012 at 10:00am PT |
| Encore at the Wynn, Las Vegas, NV |
A live audio webcast and 14-day archive of the Bank of America presentation will be available at http://ir.raptorpharma.com/events.cfm
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase deficiency ("ALDH2"), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180